alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.127 Membership of TEPRSSC. ( a ) The Commissioner will appoint the members after consultation with public and private organizations concerned with the technical aspect of electronic product radiation safety. TEPRSSC consists of 15 members, each of whom is technically qualified by training and experienced in one or more fields of science or engineering applicable to electronic product radiation safety, as follows: ( 1 ) Five members selected from government agencies, including State and Federal Governments.
( 2 ) Five members selected from the affected industries after consultation with industry representatives.
( 3 ) Five members selected from the general public, of whom at least one shall be a representative of organized labor.
( b ) The Commissioner will appoint a committee member as Chairperson of TEPRSSC.
( c ) Appointments of members are for a term of 3 years or as specified by the Commissioner. ( 1 ) The Chairperson is appointed for a term concurrent with the Chairperson's term as a member of TEPRSSC. If the Chairpersonship becomes vacant without adequate notice, the Designated Federal Officer may appoint a committee member as temporary Chairperson pending appointment of a new Chairperson by the Commissioner.
( 2 ) Members may not be reappointed for a second consecutive full term.
( d ) A person otherwise qualified for membership is not eligible for selection as a member of TEPRSSC from Government agencies or the general public if the Commissioner determines that the person does not meet the requirements of the conflict of interest laws and regulations.
( e ) Retention of membership is conditioned upon the following: ( 1 ) Continued status as a member of the group from which the member was selected as specified in paragraph (a) of this section.
( 2 ) Absence of any conflict of interest during the term of membership as specified in paragraph (d) of this section.
( 3 ) Active participation in TEPRSSC activities.
( f ) Appointment as a member of TEPRSSC is conditioned on certification that the prospective member: ( 1 ) Agrees to the procedures and criteria specified in this subpart.
( 2 ) Has no conflict of interest as specified in paragraph (d) of this section.
( 3 ) Will notify the Designated Federal Officer of TEPRSSC before any change in representative status on TEPRSSC which may be contrary to the conditions of the appointment.
( g ) Members of TEPRSSC who are not full-time officers or employees of the United States receive compensation under § 14.95, in accordance with 42 U.S.C. 210(c).
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 00-2477

EDWARD L. FLOYD,

Plaintiff - Appellant,

versus

INTERNATIONAL BUSINESS MACHINES CORPORATION,

Defendant - Appellee.

Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. W. Earl Britt, Senior District Judge. (CA-99-191-BR-5)

Submitted: April 13, 2001 Decided: May 2, 2001

Before WIDENER, LUTTIG, and TRAXLER, Circuit Judges.

Dismissed in part and affirmed in part by unpublished per curiam

opinion.

Edward L. Floyd, Appellant Pro Se. Thomas Samuel Williamson, Jr.,

COVINGTON & BURLING, Washington, D.C., for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Edward L. Floyd appeals the district court's orders dismissing

with prejudice his Fair Labor Standards Act suit and denying his

motion for reconsideration of that order.

Parties are accorded thirty days after entry of the district

court’s final judgment or order to note an appeal, see Fed. R. App.

P. 4(a)(1), unless the district court extends the appeal period

under Fed. R. App. P. 4(a)(5) or reopens the appeal period under

Fed. R. App. P. 4(a)(6). This appeal period is “mandatory and

jurisdictional.” Browder v. Director, Dep’t of Corr., 434 U.S.

257, 264 (1978) (quoting United States v. Robinson, 361 U.S. 220,

229 (1960)).

The district court’s order dismissing Floyd’s suit was entered

on the court’s docket on July 20, 2000. Appellant’s notice of appeal was filed on October 24, 2000. Floyd did not file his motion

to reconsider within ten days of the district court's order dismissing his suit, consequently the time period for filing his

appeal of that order was not tolled. See Fed. R. App. P. 4(a)(4);

Panhorst v. United States, 241 F.3d 367, 370 (4th Cir. 2001).

Therefore, Floyd's appeal is timely only as to the district court's

denial of his subsequent motion for reconsideration, construed here

under Fed. R. Civ. P. 60(b). See, e.g., Small v. Hunt, 98 F.3d

789, 797 (4th Cir. 1996).
3

This Court reviews a denial of a Rule 60(b) motion for abuse

of discretion. See NOW v. Operation Rescue, 47 F.3d 667, 669 (4th

Cir. 1995) (per curiam). We have reviewed the record and conclude

that the district court's denial of Floyd's motion for reconsideration was not an abuse of discretion.

Accordingly, we dismiss Floyd's appeal of the district court's

order dismissing with prejudice his Fair Labor Standards Act suit

for lack of jurisdiction because Floyd's notice of appeal was untimely as to that order. We affirm the district court's denial of

Floyd's motion for reconsideration. Floyd's motion for leave to

file a reply brief is denied. We dispense with oral argument because the facts and legal contentions are adequately presented in

the materials before the court and argument would not aid the

decisional process.

DISMISSED IN PART; AFFIRMED IN PART
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.5 General provisions for direct food additives. ( a ) Regulations prescribing conditions under which food additive substances may be safely used predicate usage under conditions of good manufacturing practice. For the purposes of this part, good manufacturing practice shall be defined to include the following restrictions. ( 1 ) The quantity of the substance added to food does not exceed the amount reasonably required to accomplish its intended physical, nutritive, or other technical effect in food.
( 2 ) Any substance intended for use in or on food is of appropriate food grade and is prepared and handled as a food ingredient.
( b ) The existence of a regulation prescribing safe conditions of use for a food additive shall not be construed to relieve the use of the substance from compliance with any other provision of the Act.
( c ) The existence of any regulation prescribing safe conditions of use for a nutrient substance does not constitute a finding that the substance is useful or required as a supplement to the diet of humans.
I am writing regarding the Grant application by the Rhode Island Airport Corporation to take part in the

Small Community Air Service Development Program. Please incorporate these comments, as appropriate, in objection to that application: New England Airlines has been offering scheduled, frequent, daily, year - round service to the Block Island Community for forty -two years. This service includes 24 - hour emergency medical transportation for Island residents and visitors. The profitable but short summer/tourist season allows us to self
- subsidize the full year - around service to this Island Community. Any service that would dilute this seasonal market would, without question, jeopardize the year - round regular and “life - line” service we provide. Passenge rs who need to travel through the Providence airport currently have three travel options to and from Block Island: 1. A direct, convenient charter flight with either New England Airlines or any one of the several other local - area charter operators. 2. Ground t ransportation to connect with our frequent (hourly - shuttle) flights– ten - minute flights between Westerly, RI and Block Island. 3. Ground transportation to the frequent, seasonal ferry service. (Ferries run about every hour during the summer season) Air Flam enco provides a very similar service to Culebra, year- round, including emergency 24 hour medical transport in cooperation with the local government and medical facility. Air Flamenco, until yesterday, was not aware of this Application or the D.O.T. Progr am that makes the Grant available. New England Airlines was not aware of the existence of this program until only days before the application’s submission. To say, as is stated, that New England Airlines is not interested in expanding our service to incl ude Providence is NOT TRUE! Given the short notice by the Rhode Island Airport Corporation(RIAC) to be a part of this application, it was an impossibility to do so. Cape Air management unequivocally stated that they had been working with RIAC for “severa l years” toward this end! Between Air Flamenco and New England Airlines, we together already operate fifteen of the type aircraft that Cape Air proposes to purchase specifically for this service, in addition to a variety of other aircraft types. Please a lso note that although an application of this nature usually bears more strength when it includes backing for this “new” service by local tourism and government entities, there is no such support from either Block Island or Culebra. Respectfully submitted , William G. Bendokas, President New England Airlines, Inc.
<PAGE>   1

                                                                    EXHIBIT 21.1

                         SUBSIDIARIES OF THE REGISTRANT

        Name                                   State of Incorporation
        ----                                   ----------------------
        AGI Distribution, Inc.                         Nevada
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.30 Annual reports of holder of orphan-drug designation. Within 14 months after the date on which a drug was designated as an orphan drug and annually thereafter until marketing approval, the sponsor of a designated drug shall submit a brief progress report to the FDA Office of Orphan Products Development on the drug that includes: ( a ) A short account of the progress of drug development including a review of preclinical and clinical studies initiated, ongoing, and completed and a short summary of the status or results of such studies.
( b ) A description of the investigational plan for the coming year, as well as any anticipated difficulties in development, testing, and marketing; and
( c ) A brief discussion of any changes that may affect the orphan-drug status of the product. For example, for products nearing the end of the approval process, sponsors should discuss any disparity between the probable marketing indication and the designated indication as related to the need for an amendment to the orphan-drug designation pursuant to § 316.26.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1754 Sodium diacetate. ( a ) Sodium diacetate (C4H7O4Na·xH2O, CAS Reg. No. 126-96-5) is a molecular compound of acetic acid, sodium acetate, and water of hydration. The technical grade is prepared synthetically by reacting sodium carbonate with acetic acid. Special grades are produced by reacting anhydrous sodium acetate and acetic acid.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 284, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) The ingredient is used as an antimicrobial agent as defined in § 170.3(o)(2) of this chapter; flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter; and pH control agent as defined in § 170.3(o)(23) of this chapter.
( d ) The ingredient is used in food at levels not to exceed current good manufacturing practice in accordance with § 184.1(b)(1). Current good manufacturing practice results in a maximum level, as served, 0.4 percent for baked goods as defined in § 170.3(n)(1) of this chapter; 0.1 percent for fats and oils as defined in § 170.3(n)(12) of this chapter, meat products as defined in § 170.3(n)(29) of this chapter and soft candy as defined in § 170.3(n)(38) of this chapter; 0.25 percent for gravies and sauces as defined in § 170.3(n)(24) of this chapter; and 0.05 percent for snack foods as defined in § 170.3(n)(37) of this chapter and soups and soup mixes as defined in § 170.3(n)(40) of this chapter.
( e ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[47 FR 27815, June 25, 1982]
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.720 Calcium lactobionate. The food additive calcium lactobionate may be safely used in food in accordance with the following prescribed conditions: ( a ) The food additive is the calcium salt of lactobionic acid (4-(β,D-galactosido)-D-gluconic acid) produced by the oxidation of lactose.
( b ) It is used or intended for use as a firming agent in dry pudding mixes at a level not greater than that required to accomplish the intended effect.
<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              MAY-31-1998
<PERIOD-END>                                   MAY-31-1998
<CASH>                                              49,108
<SECURITIES>                                             0
<RECEIVABLES>                                        9,250
<ALLOWANCES>                                             0
<INVENTORY>                                        122,134
<CURRENT-ASSETS>                                   200,660
<PP&E>                                             106,598
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                     318,540
<CURRENT-LIABILITIES>                              719,585
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                            11,966
<OTHER-SE>                                        (413,011)
<TOTAL-LIABILITY-AND-EQUITY>                       318,540
<SALES>                                              9,073
<TOTAL-REVENUES>                                     9,073
<CGS>                                                    0
<TOTAL-COSTS>                                            0
<OTHER-EXPENSES>                                10,004,726
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  17,548
<INCOME-PRETAX>                                 (1,112,594)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                      0
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (1,112,594)
<EPS-PRIMARY>                                          .10
<EPS-DILUTED>                                          .10
        

</TABLE>
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8979]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3929]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel, Review of Minority Biomedical 
Research Support Applications.
    Date: March 22, 2010.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency, Bethesda, MD 20814.
    Contact Person: Rebecca H. Johnson, PhD, Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, Natcher Building, 
Room 3AN18C, Bethesda, MD 20892. 301-594-2771. 
<a href="/cdn-cgi/l/email-protection#a7cdc8cfc9d4c8c9d5cfe7c9cec0cad489c9cecf89c0c8d1"><span class="__cf_email__" data-cfemail="3e545156504d51504c567e505759534d1050575610595148">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: February 19, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3929 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 310.537 Drug products containing active ingredients offered over-the-counter (OTC) for oral administration for the treatment of fever blisters and cold sores. ( a ) l-lysine (lysine, lysine hydrochloride), *Lactobacillus acidophilus,* and *Lactobacillus bulgaricus* have been present in orally administered OTC drug products to treat fever blisters and cold sores. There is a lack of adequate data to establish general recognition of the safety and effectiveness of these or any other orally administered ingredients for OTC use to treat or relieve the symptoms or discomfort of fever blisters and cold sores. Based on evidence currently available, any OTC drug product for oral administration containing ingredients offered for use in treating or relieving the symptoms or discomfort of fever blisters and cold sores cannot be generally recognized as safe and effective.
( b ) Any OTC drug product for oral administration that is labeled, represented, or promoted to treat or relieve the symptoms or discomfort of fever blisters and cold sores is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product for oral administration labeled, represented, or promoted for OTC use to treat or relieve the symptoms or discomfort of fever blisters and cold sores is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After December 30, 1992, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[57 FR 29173, June 30, 1992]
##### 



EXHIBIT 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley
Act of 2002, I, David H. Thompson, Chief Financial Officer, certify that:  1.
    
    To my knowledge, this report fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.
    
    To my knowledge, the information in this report fairly presents, in all
material respects, the financial condition and results of operations as of
October 31, 2004. Date: December 8, 2004 /s/ David H. ThompsonDavid H. ThompsonChief Financial Officer 29
[No. 39224-7-I.

Division One.

November 17, 1997.]

#### The State of Washington, *Respondent,*v. J.R., *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-8-03079-3, Michael Spearman, J., entered July 26, 1996. *Affirmed*by unpublished opinion per Ellington, J., concurred in by Baker, C.J., and Grosse, J.
I 

118TH CONGRESS 

2D SESSION H. R. 7382 

To amend the Omnibus Crime Control and Safe Streets Act of 1968 to 

include an additional permissible use of amounts provided as grants 

under the Byrne JAG program, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Mr. LUTTRELL (for himself, Mr. MCCAUL, Mrs. WAGNER, Mrs. CHAVEZDEREMER, Ms. SALAZAR, Mr. BACON, Ms. MACE, Mrs. MILLER-MEEKS, 

Mrs. GONZA ́LEZ-COLO ́N, Mr. CRENSHAW, Mr. STAUBER, Mr. ELLZEY, 

and Mr. DELUZIO) introduced the following bill; which was referred to 

the Committee on the Judiciary 

A BILL 

To amend the Omnibus Crime Control and Safe Streets 

Act of 1968 to include an additional permissible use 

of amounts provided as grants under the Byrne JAG 

program, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Empowering Law En5 forcement To Fight Sex Trafficking Demand Act of 

6 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7382 IH

1 SEC. 2. ADDITIONAL AUTHORIZED USE OF BYRNE JAG 

2 FUNDS. 

3 Section 501(a)(1) of the Omnibus Crime Control and 

4 Safe Streets Act of 1968 (34 U.S.C. 10152(a)(1)) is 

5 amended by adding at the end the following: 

6 ‘‘(I) Programs to combat human traf7 ficking (including programs to reduce the de8 mand for trafficked persons).’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB